BioFund RVC closed the first deal in St. Petersburg

BioFund RVC announces the establishing of the Center for bioequivalence research (BioEq) based in St. Petersburg together with a group of private investors. The new company will operate in strict accordance with international standards, it will speed up the research activities and it is needed to meet market requirements.

Bioequivalence research center will conduct Phase I clinical trials in accordance with international standards GCP. The project team includes a number of professionals with extensive experience in the industry, a number of agreements with leading global CRO and pharmaceutical companies for consultations and training has been also concluded.

Existing centers of clinical research are usually government research institutes specialized in the later stages of clinical trials and they can not always meet all the needs of the market. As the director of BioFund RVC Egor Beketov says, today there are few centers in the country that can provide services that meet international standards of quality in timely manner, so that the attractiveness of the domestic market of clinical bioequivalence phases and early stages remains low compared to later phases.

Our center will be able to take its rightful place in the market of clinical trials, owing to the professional team - the director of BioEq Company Ivan Sardaryan said. - We will quickly respond to market demands and try to meet the highest customers’ requirements. To date, we have already prepared several contracts with domestic and foreign producers.